EAVI2020 EAVI2020 on Twitter EAVI2020 on LinkedIn

World AIDS DAY Part 1: EAVI2020’s research to a better future | Trial EAVI2020_3Sm

info card on clinical trial EAVI2020 - 3SM

Hi! I’m the EAVI2020-3Sm trial and I am testing the VAC02 vaccine. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly Neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. VAC02 is an HIV vaccine candidate based on discovery of the immunogenicity of a conserved gp41 peptide, namely W614A-3S, recognized by natural broadly neutralizing Ab detected in HIV-1 infected individuals. It is composed of gp41-3Sm peptide that is coupled to CRM197 in an adjuvant formulation. The first in man clinical trial will discern the safety and the immunogenicity of VAC02 as well as the induction of broadly neutralizing antibodies against HIV-1.

Let me introduce you the team: Robin Shattock (Imperial College London, Study sponsor, UK), Behazine Combadiere, Vincent Vieillard and Patrice Debre (Institut National de Santé et de Recherche Medicale – Inserm, Cimi-Paris, France), Agence Nationale de Recherche sur le SIDA et Maladies Infectieuses Emergentes (ANRS-MIE, France) and Minka Therapeutics (France), they all work together to ensure I am successful!

Progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Peptide-based vaccination has become one of the challenges of this decade. Based on the discovery of natural broadly neutralizing antibodies against a conserved short epitope of GP41 in long-term non progressor HIV+ patients however rarely observed in HIV progressors, the EAVI2020-3Sm trial will be pioneering in the induction of such antibodies against HIV in man using VAC02 designed vaccine. Furthermore, the translation of VAC02 vaccine candidate into an experimental medicine (EM) study with results expected in 2022 will accelerate progress in the development of an HIV-1 vaccine.

Find out more about the other EAVI2020 trials taking place:

info card on clinical trial HIV-CORE 0051

HIV-CORE 0051

info card on clinical trial HIV-CORE 0052

HIV-CORE 0052

info card on clinical trial EAVI2020_01

EAVI2020-01

info card on clinical trial BCN03

BCN03

Follow World AIDS Day campaigns on Twitter with #Rocktheribbon

To donate and show your support, go to the National AIDS Trust website

For World AIDS Day 2022, the EAVI2020 clinicians and researchers are shedding a light on the EAVI2020 clinical trials that aim to help accelerate the search for an effective HIV vaccine. Every year on 1st December since 1988, World AIDS Day is an international day dedicated to raising awareness of the AIDS pandemic caused by the spread of the HIV virus. According to WHO, since the beginning of the pandemic, 36.3 million people have lost their lives and it was estimated that there were 37.7 million people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region.

It is a day to remember those who have perished due to AIDS and that international research projects such as EAVI2020, are continuing the fight to find an effective vaccine for the HIV virus that has so far evaded eradication for the past 30+ years. Learn more about EAVI2020’s clinical trials and what the dedicated consortium of researchers and clinicians aim to achieve.

Latest Posts

graphic illustration of red blood cells around a HIV virus cell
The Quest for an HIV…
June 24, 2022
World AIDS Vaccine Day…
May 18, 2022
Professor Gabriella Scarlatti hosting a panel, with Professor Robin Shattock and Dr Hans Langedijk in view
What’s next for…
April 28, 2022